Topoisomerase II inhibition involves characteristic chromosomal expression patterns

BMC Genomics

Table 1 Number of genes found in different window sizes.

	Window sizes analyzed [kbp]	Expected number of genes (100 randomized gene lists)	Standard deviation	Observed number of regulated genes	Significance (p-value)
Aroclor (599)	0–50	15.07	3.23	34	0.00000857
	50–100	13.70	3.97	19	0.03657915
	100–200	24.62	4.60	25	0.08103966
Trovafloxacin (1530)	0–50	84.51	9.38	92	0.03045474
	50–100	77.16	7.71	110	0.00005667
	100–200	127.52	9.30	143	0.01301018
Doxorubicin (580)	0–50	13.33	3.61	21	0.01286883
	50–100	13.46	3.59	25	0.00140735
	100–200	23.73	4.83	23	0.08357927
Etoposide (704)	0–50	18.89	4.22	43	0.00024071
	50–100	18.50	4.44	46	0.00336279
	100–200	34.56	4.78	81	0.00065127
c-myc (899)	0–50	30.82	5.36	23	0.02745216
	50–100	29.27	5.67	29	0.07500742
	100–200	52.18	7.53	60	0.02919296

Comparison of the gene lists resulting from treatment with different topoisomerase II inhibitors or from overexpression of c-myc with the mean of 100 randomized gene lists. For each window size, the expected number of genes is shown along with the observed number of genes. The expected numbers of genes result from the mean of 100 randomized gene lists comprising the same number of genes as the respective regulated gene list. Furthermore, the p-value is shown for obtaining such a result by chance using the binominal distribution. Whenever the difference between the expected number of genes and the observed number of regulated genes is significant, the corresponding values are marked bold (expected number < observed number) or italic (expected number > observed number).

ISSN: 1471-2164